The strong Phase 2b data materially de-risks volixibat's regulatory path in PSC. Monitor for the pre-NDA meeting outcome and any updates on the NDA submission timeline. The VANTAGE PBC readout in Q1 2027 adds a near-term pipeline catalyst.
Price Chart
Executive Summary
Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in PSC, meeting the primary endpoint with high statistical significance (p<0.0001) and a robust placebo-adjusted improvement in pruritus. The company plans a pre-NDA meeting with the FDA in summer 2026 and an NDA submission in H2 2026, positioning volixibat as a potential first treatment for cholestatic pruritus in PSC.
Key Facts
- Primary endpoint met in VISTAS Phase 2b study of volixibat in PSC (p<0.0001).
- Placebo-adjusted improvement of 1.64 points on Adult ItchRO scale.
- 55.6% of volixibat patients achieved 2-point reduction vs 26.3% for placebo (p=0.0019).
- Pre-NDA meeting with FDA scheduled for summer 2026; NDA submission planned H2 2026.
- Safety profile consistent with IBAT inhibition; GI and liver enzyme elevations observed.
- Topline data from VANTAGE Phase 2b study in PBC expected Q1 2027.
Financial Impact
No financial figures reported; positive Phase 2b data supports regulatory advancement and potential to address an unmet medical need.
Risk Factors
- Safety signals including GI adverse events and liver enzyme elevations may raise regulatory concerns.
- NDA submission and FDA approval are not guaranteed; additional trials or data may be required.
- Competition from other therapies in development for PSC-related pruritus.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202609 |
| Document: 0001193125-26-202609-index-headers.html | 0001193125-26-202609 |
| Document: 0001193125-26-202609-index.html | 0001193125-26-202609 |
| Document: 0001193125-26-202609.txt | 0001193125-26-202609 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $102.24 $98.82 | ▼ −3.35% | ▼ −1.39% | $82.58 (−19.23%) |
Aug 12, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▲ +1.66% | ▲ +3.55% | $82.58 (−16.56%) |
Aug 11, 2026 7w ago | Insider Cluster | $98.97 $100.61 | ▼ −1.66% | ▼ −3.55% | $82.58 (+16.56%) |
Aug 10, 2026 7w ago | 144 | $98.23 $98.30 | ▲ +0.07% | ▲ +1.13% | $82.58 (−15.93%) |
Aug 5, 2026 8w ago | 8-K | $94.12 $100.63 | ▲ +6.92% | ▲ +6.32% | $82.58 (−12.26%) |
Jul 8, 2026 12w ago | Insider Cluster | $128.57 $105.79 | ▼ −17.72% | ▼ −20.99% | $82.58 (−35.77%) |
Jun 11, 2026 16w ago | Institutional Cluster | $99.54 $127.70 | ▲ +28.29% | ▲ +26.40% | $82.58 (−17.04%) |
Jun 10, 2026 16w ago | Insider Cluster | $94.00 $127.70 | ▲ +35.85% | ▲ +32.23% | $82.58 (−12.15%) |
Jun 2, 2026 17w ago | Insider Cluster | $91.84 $125.59 | ▲ +36.76% | ▲ +37.76% | $82.58 (−10.08%) |
Jun 1, 2026 17w ago | 144 | $92.17 $120.46 | ▲ +30.69% | ▲ +32.26% | $82.58 (−10.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access